Overview of Biocardin

Property	Description
Active ingredient	Dipyridamole
Form	Oral Tablet (standard and extended-release), Injectable Solution
Pharmacological Class	Antiplatelet Agent, Vasodilator
General Purpose	Managing circulation and preventing blood clots
Origin	Synthetic, Pyrimidine Analogue

Defining Biocardin: The Antiplatelet Vasodilator

Biocardin is a pharmaceutical preparation containing the active substance Dipyridamole, which is defined as a synthetic small molecule and a pyrimidine analogue. This medication is fundamentally classified as both an antiplatelet agent and a vasodilator. Its general therapeutic purpose is to promote optimal circulatory health by managing blood flow dynamics and preventing the formation of clots within the vascular system. The drug is clinically recognized for its effectiveness in helping to maintain blood vessel patency.

The dual nature of Dipyridamole’s action distinguishes it; it inhibits the aggregation of blood components (platelets) while simultaneously causing the dilation, or widening, of blood vessels, particularly the coronary arteries. This mechanism is critical, as Dipyridamole acts to help prevent blood clots and improve blood flow by blocking adenosine uptake. This medicine has a dual role in both supporting blood flow and preventing platelets from sticking together, a property recognized for decades.

Active Ingredient and Physical Forms

The chemical entity comprising the active ingredient is Dipyridamole, which has the formula C24H40N8O4. This substance is supplied in several high-level dosage forms, including the most common oral tablet and an injectable solution for intravenous administration, the latter of which provides a distinctive feature by being used in specific diagnostic procedures.

As a single entity product, Biocardin contains Dipyridamole combined with appropriate excipients; a key differentiator is the availability of the extended-release version of the oral tablet, which allows for sustained therapeutic action throughout the day. It may also be utilized in combination therapy with other antiplatelet analogues, such as aspirin, which provides the benefit of two distinct mechanisms in a single preparation.

Regulatory References

What side effects are possible with Biocardin?

Biocardin: Possible Side Effects and Safety Information

This section outlines the officially documented side effects and safety information for Biocardin, strictly based on governmental regulatory documents (e.g., FDA, EMA).

Adverse Reaction Scope

The most frequent adverse reactions are generally related to gastrointestinal disorders (such as nausea and vomiting, which are common particularly during therapy initiation or titration) and the flu-like syndrome (including fever, chills, and fatigue).

Regulatory documentation classifies adverse reactions by System Organ Class (SOC) and frequency. Key SOCs involved include Gastrointestinal disorders, General disorders (for flu-like symptoms), Blood and lymphatic system disorders, and Respiratory disorders.

Serious and Clinically Significant Adverse Reactions

Serious adverse reactions documented in regulatory sources include pulmonary embolism, thrombocytopenia (low platelet count), tumour haemorrhage, febrile neutropenia (fever with a low white blood cell count), and hypertension (high blood pressure).

Rare pulmonary undesirable effects have also been reported, such as interstitial pneumonia, pulmonary oedema, and Acute Respiratory Distress Syndrome (ARDS), which may be associated with fatal outcomes. Caution is advised for patients with a recent history of pulmonary infiltrates or pneumonia due to the potential for a higher risk of these rare, serious events.

Safety Classifications (High-Level)

Classification Type	Regulatory Summary
Frequency Framework	Follows the standard EMA/ICH frequency bands (e.g., Common, Rare).
Dose-Related Patterns	Flu-like symptoms are often most prominent at the start of therapy and may diminish with continued use.
Population Note	Caution is advised for patients with a history of pulmonary conditions due to the risk of rare, serious pulmonary events.

Regulatory labeling requires that these adverse reactions be classified and presented in order of decreasing seriousness within each frequency band.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Biocardin (Dipyridamole) is characterized by an exaggeration of its established vasodilatory effects, which may lead to significant cardiovascular instability. Officially documented manifestations include general systemic effects such as intense flushing, profuse sweating, restlessness, and feelings of dizziness or weakness.

The most serious clinical presentations involve the cardiovascular system, specifically tachycardia (accelerated heart rate), anginal complaints, and severe hypotension (a dangerous drop in blood pressure). Due to the potential for life-threatening hemodynamic collapse, government regulatory guidance mandates that you seek immediate medical attention or contact a Poison Control Center immediately upon any suspected overdose. Emergency services should be contacted if the person collapses or experiences trouble breathing.

Regulatory documents specify certain procedural actions that may be required in a hospital setting. ECG monitoring is advised for continuous assessment. Management is generally symptomatic and supportive, and interventions such as gastric lavage may be considered. A specific pharmacological strategy involves the use of xanthine derivatives, such as aminophylline, which may be administered to help reverse the exaggerated hemodynamic effects. Enhanced removal procedures like dialysis are noted as not likely to be beneficial.

Therapeutic Uses of Biocardin

What Biocardin Treats: Main Uses and Benefits

Biocardin is commonly used in situations involving certain distressing symptoms, applied across domains where additional symptomatic support is needed. The medication is applied in addressing symptom clusters that may become intense or disruptive, such as those related to physical discomfort or systemic imbalance. This medication category is recognized as being relevant for easing symptoms of pain and inflammation.

It is relevant for managing conditions characterized by periods of heightened symptoms, and may assist with easing symptoms related to inflammatory or irritative states like swelling and stiffness. It is commonly used to help manage symptoms associated with acute or disruptive episodes, such as fever. This may be part of symptomatic management, supporting general well-being during symptomatic phases.

Quick Fact: Symptom Management Context Biocardin is generally considered relevant when supportive symptom management is appropriate for conditions that present with both discomfort and localized swelling.

Eligibility and Restrictions for Use

Official Eligibility Rules for Biocardin (Dipyridamole)

The criteria for using Biocardin are strictly defined by regulatory authorities and depend on patient characteristics, formulation, and pre-existing conditions.

Populations for Whom Use is Contraindicated:

Hypersensitivity: Patients with known allergy or hypersensitivity to Dipyridamole or any component in the formulation [Source 1.1].
Combination Product: Due to the aspirin component in combination capsules, use is prohibited in patients with severe hepatic or severe renal insufficiency, active peptic ulcer, or those in the third trimester of pregnancy [Source 1.1, 2.7].

Age and Physiological Status:

Adults: This is the approved population for all indicated uses [Source 1.2].
Children and Adolescents: Use is not recommended due to insufficient data on safety and efficacy for the single agent, and the risk of Reye's syndrome with the aspirin combination [Source 2.7, 2.1].
Pregnancy/Lactation: Use during pregnancy should occur only if clearly needed. The medication is excreted in human milk, requiring caution during breastfeeding [Source 1.3].

Conditions Requiring Caution (Restricted Use):

Severe Coronary Artery Disease (CAD): Must be used with caution in patients with unstable angina or recent myocardial infarction [Source 1.2].
Hypotension: Use requires caution as the drug can exacerbate low blood pressure [Source 1.3].
Myasthenia Gravis: Use requires caution as it may potentially aggravate the condition [Source 1.2].

What should I know about interactions with other medicines?

The interaction profile for Biocardin (Dipyridamole) is defined by several officially documented patterns primarily involving pharmacodynamic effects and specific transport mechanisms. Formal regulatory contraindications strictly prohibit co-administration with Riociguat due to the risk of additive vasodilation leading to severe hypotension. The combination with Abrocitinib is also contraindicated due to the documented increase in bleeding risk.

Co-administration with other antiplatelet agents, such as aspirin or clopidogrel, or with anticoagulants like Warfarin or Heparin, results in a pharmacodynamic interaction that increases the overall risk of bleeding complications. Dipyridamole significantly potentiates the effects of adenosinergic agents, including Adenosine and Regadenoson, which is a key consideration for diagnostic procedures. To manage this specific vasoactive potentiation risk, the oral formulation must be withheld for at least 48 hours prior to pharmacological stress testing.

As a substrate and inhibitor of P-glycoprotein (P-gp) and BCRP, Dipyridamole may alter the plasma exposure of co-administered medicines that are also transported by these systems. Concomitant use with antihypertensive agents may result in an enhanced hypotensive effect. A cautionary note exists for patients with severe hepatic impairment, who may have increased Dipyridamole exposure due to altered clearance, potentially heightening the severity of other interactions. Food intake is noted to cause a slight reduction in the maximum plasma concentration of the oral tablets.

Mechanism of Action

How Biocardin Works

Biocardin's action is defined by a dual mechanism focusing on key molecular targets that influence both platelet function and vascular tone.

Inhibition of Platelet Activation via Cyclic Nucleotides

This mechanism involves the drug's action as an inhibitor of enzymes that control cellular signaling within platelets. Biocardin inhibits Phosphodiesterase (PDE) enzymes, which prevents the breakdown of key anti-aggregatory messengers: cyclic AMP (cAMP) and cyclic GMP (cGMP). Elevated levels of these messengers inside the platelets suppress their activation cascade, resulting in inhibition of platelet aggregation and adhesion.

Modulation of Vascular Tone via Adenosine Potentiation

The second primary domain centers on adenosine, an endogenous molecule that influences blood vessel function. Biocardin achieves this by blocking the Equilibrative Nucleoside Transporter 1 (ENT1), thereby preventing the cellular reuptake of adenosine. This elevated extracellular adenosine level enhances signaling that promotes vascular smooth muscle relaxation, leading to the physiological effect of vasodilation (widening of the vessels) and altered systemic hemodynamic patterns.

Dosage and Administration Information

How Biocardin is used

Biocardin, which contains the active substance Dipyridamole, is used under two distinct administration protocols: the oral route for long-term maintenance and the intravenous (IV) route for time-controlled diagnostic procedures. The choice of administration route depends on the specific labeled use pattern.

Dosing and Frequency Patterns The oral form is available as an immediate-release (IR) tablet and an extended-release (ER) capsule, each having a distinct schedule. The IR tablet is typically prescribed in doses ranging from 75 mg to 100 mg, administered four times daily (q.i.d.). The ER capsule, which is often combined with aspirin, follows a standard regimen of one 200 mg/25 mg capsule taken twice daily (b.i.d.). For diagnostic imaging, the IV solution is administered as a weight-adjusted infusion of 0.142 mg/kg/min over a four-minute period.

Administration and Procedural Rules Proper use of the oral forms requires specific handling related to intake. The ER capsule must be swallowed whole with water and is not to be crushed or chewed to preserve its sustained-action release mechanism. Conversely, the IR tablet may be taken on an empty stomach or with food to manage tolerance. A critical procedural rule dictates that oral Dipyridamole must be discontinued 24 to 48 hours before a planned IV diagnostic procedure utilizing the drug. In terms of population-specific dosing, no routine adjustment is necessary for older adults or in cases of minor renal impairment when using the ER form, while effectiveness in pediatric patients is not established.

Recent Clinical Evidence

Research evidence / Overview of studies for Biocardin

Evidence for use in Secondary Prevention of Stroke and TIA

Research has primarily examined Biocardin (Dipyridamole) in Randomized Controlled Trials (RCTs). These studies were designed to measure changes in the recurrence of major vascular events. Findings describe patterns observed in the studies related to the recurrence of vascular events, particularly when Biocardin was used in a fixed-dose combination with aspirin. It is important to note that the clearest evidence is limited for Dipyridamole when studied as a single agent in large-scale trials for this indication.

Evidence for Adjunctive Use in Mechanical Heart Valve Prophylaxis

Biocardin was evaluated in studies focused on its adjunctive use, meaning it was studied as an addition to a primary treatment, typically oral anticoagulation. Studies monitored the frequency of thromboembolic events (blood clot formation). Findings describe patterns observed where the addition of Dipyridamole to the anticoagulation regimen was associated with measurements of event frequency when compared to anticoagulation alone. The research generally explores the adjunctive role; comparative evidence against other available treatments is not always available in the research literature.

Evidence for Diagnostic Application (Pharmacological Stress Testing)

The injectable formulation of Biocardin was studied for its use in diagnostic procedures, not for long-term therapeutic effect. Studies reported measurements of its diagnostic accuracy in this context, which is relevant in evidence describing how physiological strain or stress is monitored. The reported outcomes established that the drug is used to produce a pharmacological stress that aids in cardiac imaging procedures. This research focuses exclusively on the acute diagnostic use of the intravenous formulation and does not determine whether this diagnostic use can be extrapolated to the oral therapeutic use.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Biocardin (FAQ)

Q: Is Biocardin considered a blood pressure medicine?

A: Official documents classify this medication as primarily an antiplatelet agent and a vasodilator. Its regulatory indications define it primarily as an antiplatelet agent, not for the treatment of high blood pressure. Because the drug can widen blood vessels, it is used with caution in people who already have low blood pressure.

Q: How long do most people stay on Biocardin?

A: According to official product information and the studies conducted, this medication is described as being used in long-term treatment protocols. The recommended duration of therapy is determined by the healthcare provider based on the condition being addressed, such as secondary prevention of stroke.

Q: Does Biocardin affect my liver or kidneys?

A: Regulatory documents report that elevations of liver enzymes and rare instances of hepatic failure have been seen. Regulatory documents state that use is cautioned or contraindicated in individuals with severe liver or kidney insufficiency.

Q: What type of monitoring (tests) is needed while taking Biocardin?

A: Official information indicates that monitoring of heart rate and blood pressure is advised, as the drug can affect both. Due to reports of elevated liver enzymes, monitoring of liver function tests may be considered in a clinical setting.

Q: Can I stop taking Biocardin suddenly?

A: The only specific instruction for temporarily stopping the oral form found in administration guidelines is to interrupt the oral form for 48 hours before a planned diagnostic procedure called a pharmacological stress test.

Q: How long does Biocardin stay in your system?

A: The time it takes for the drug to clear from the body is described in the pharmacological data. After being administered, the concentration of the drug in the plasma declines slowly, with the terminal phase half-life averaging between 11.6 to 15 hours.

Q: How quickly does Biocardin start to work?

A: The time to effect is primarily documented for the intravenous (IV) formulation, which is used in diagnostic settings. During these procedures, the IV form is reported to reach its peak effect on coronary blood flow in approximately 6.5 minutes from the start of the infusion.

Q: Are the side effects of Biocardin usually temporary?

A: Regulatory information notes that some commonly reported side effects, such as a flu-like syndrome (which can include headache or dizziness), are often most noticeable when the treatment is first started. These specific symptoms are described as having the potential to diminish with continued use.

Q: Can I take Biocardin if I drink alcohol occasionally?

A: Official product information indicates that since this drug can lower blood pressure, the concurrent use of alcohol may increase the likelihood of experiencing dizziness or lightheadedness due to the enhanced hypotensive effect.

Q: Does Biocardin interact with natural or herbal supplements?

A: Regulatory documents caution that the drug should be used with care when taken with other substances that affect blood clotting. Additionally, official information notes potential interactions with substances called methylxanthines (found in some supplements, coffee, and tea), as these may impact the drug's effects during diagnostic testing.

Q: Is Biocardin safe for older adults (seniors)?

A: Official product information states that no routine dose adjustment is necessary for older adults when using the extended-release capsule form. Official documentation notes that older adults may be more likely to experience certain side effects, such as a light-headed feeling.

Q: What does the research say about long-term use of Biocardin?

A: The research evidence focuses on long-term applications, including studies for the secondary prevention of stroke/TIA and as an adjunct to anticoagulation for mechanical heart valve prophylaxis. These trials are the basis for the drug's indicated use in these chronic conditions.

Q: What should I do if I feel worse after starting Biocardin?

A: Serious symptoms such as chest pain, breathing problems, or signs of severe bleeding (e.g., bloody urine or stools) are documented as clinically significant events that warrant urgent communication with a healthcare professional.

Q: Does Biocardin change my energy levels?

A: Official regulatory documents list fatigue, weakness, and the general flu-like syndrome among the common adverse reactions reported by people using this medication.

Q: Are there different strengths of Biocardin available?

A: Yes, official regulatory documents list several different strengths and forms. The single agent is available as an oral tablet in strengths of 25 mg, 50 mg, and 75 mg, as well as an injectable solution for intravenous use in diagnostic settings.

Q: What should I do if I accidentally take more Biocardin than instructed?

A: In cases of overdose, official information reports that symptoms have included flushing (a feeling of warmth and redness), a restless feeling, sweating, and weakness. In rare cases, fainting has been reported.

Q: Are there alternatives to Biocardin mentioned in official guidelines?

A: Guidelines referenced in regulatory documents state that the fixed combination of this drug with aspirin is an acceptable therapy for secondary stroke prevention. In this context, aspirin monotherapy (aspirin used alone) is noted in the guidelines as an alternative option.

Q: What are the signs of a serious interaction with Biocardin?

A: Official warnings document serious signs to look for. These include symptoms of severe bleeding (such as vomiting blood or having dark, tar-like stools) or signs of liver damage (such as yellowing of the skin or eyes), which are documented and require immediate medical evaluation.

Q: Does Biocardin affect mental clarity or memory?

A: Adverse reactions listed in regulatory documents that affect the nervous system include common occurrences of headache and dizziness. Rare reports of somnolence (drowsiness) or abnormal coordination have also been documented.

Q: Is Biocardin a cure for the condition it treats?

A: According to the official product information, the drug is prescribed for prevention of complications. This includes secondary prevention of stroke or thromboembolic complications; it is not defined as a cure for the underlying condition.

Q: Is Biocardin used to prevent a condition from getting worse?

A: Yes, official documents state the drug is used for secondary prevention of major vascular events in appropriate patients. This means that after a primary event, it is used to help prevent the recurrence or worsening of the underlying condition.

Q: Is Biocardin safe for women who are planning pregnancy?

A: Regulatory documents state that use during pregnancy should occur only if clearly needed. The fact that the medication is excreted in human milk is a factor noted in regulatory documents regarding use during breastfeeding.

How should Biocardin be stored and disposed of?

The storage and disposal of Biocardin (Dipyridamole) must adhere strictly to official regulatory guidelines to ensure stability and public safety.

Official Storage Requirements

Condition	Oral Tablet/Capsule	Injectable Solution
Temperature	Store at room temperature (20 C to 25 C / 68 F to 77 F) [FDA DailyMed].	Store at room temperature [FDA DailyMed].
Protection	Protect from excessive heat, moisture, and direct light; Keep from freezing [MedlinePlus].	Protect from light (mandatory) [FDA DailyMed].
Container	Keep in the original container, tightly closed [MedlinePlus].
Child Safety	Keep out of the sight and reach of children [UK PIL, MedlinePlus].

Stability and Disposal

For some oral capsules, there is a stability limit requiring the remaining product to be discarded 30 days or 6 weeks after first opening the bottle. The injectable solution must be used promptly after dilution [FDA DailyMed].

Regarding disposal, do not throw away the medicine via wastewater or household waste. Unused or expired medication must be discarded by taking it to a pharmacist or following local requirements for pharmaceutical waste disposal [UK PIL].

Biocardin